ProCE Banner Activity

Global Perspective on BRCA Mutations, PARPi, and Biomarker-Driven Strategies in Pancreatic Cancer

Hear from global experts in this on-demand Webcast capturing a live CCO Webinar focused on leveraging PARP inhibitors and chemotherapy for optimal treatment of pancreatic cancer with BRCA1/2 and other DNA damage repair gene alterations.

Released: October 08, 2020

Expiration: October 07, 2021

No longer available for credit.

Share

Faculty

Dirk Arnold

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Michael J. Pishvaian

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Supporters

Supported by an educational grant from

AstraZeneca

Learning Objectives

  • Evaluate the clinical rationale for assessing BRCA1/2 and other DNA damage repair gene alterations in pancreatic cancer
  • Plan therapeutic strategies for patients with pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Examine the emerging role of PARP inhibitors in the frontline maintenance setting for patients with BRCA-mutant pancreatic cancer
  • Discuss the rationale for using platinum-based chemotherapy in patients newly diagnosed pancreatic cancer and germline BRCA mutations, based on available data and treatment guidelines

Faculty Disclosure

Primary Author

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Dirk Arnold, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Pierre Fabre, and Roche; funds for research support from AstraZeneca, Bristol-Myers Squibb, and Pierre Fabre; fees for non-CME/CE services from Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Pierre Fabre, and Roche; and other financial or material support from AstraZeneca.

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Michael J. Pishvaian MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Caris, Celgene, Halozyme, Ipsen, MedImmune, Merck, Merrimack, Perthera, Rafael, RenovoRx, and Sirtex; has received funds for research support from Armo, AstraZeneca, Bavarian Nordic, Bayer, Boston Biomedical, Bristol-Myers Squibb, Calithera, Celgene, Celldex, Curegenix, FibroGen, Genentech, Gilead Sciences, GlaxoSmithKline, Halozyme, Karyopharm, MedImmune, Merck, Novartis, Pfizer, Pharmacyclics, Regeneron, and Tesaro; and has ownership interest in Perthera.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.